- Home
- CVR vs SLGL Comparison
CVR vs SLGL Comparison
Compare CVR & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVR | SLGL |
|---|---|---|
| Founded | 1920 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 117.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CVR | SLGL |
|---|---|---|
| Price | $13.90 | $42.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 9.0K | ★ 16.6K |
| Earning Date | 02-08-2026 | 11-20-2025 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $26,008,045.00 | $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $8.15 | $4.02 |
| 52 Week High | $16.64 | $52.26 |
Technical Indicators
Market Signals| Indicator | CVR | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 52.92 |
| Support Level | $12.56 | $40.10 |
| Resistance Level | $14.50 | $44.99 |
| Average True Range (ATR) | 1.10 | 3.44 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 78.67 | 55.31 |
Price Performance
Historical ComparisonAbout CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.